We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report.
- Authors
Miki Koroku; Teppei Omori; Harutaka Kambayashi; Shun Murasugi; Tomoko Kuriyama; Yuichi Ikarashi; Maria Yonezawa; Ken Arimura; Kazunori Karasawa; Norio Hanafusa; Masatoshi Kawana; Katsutoshi Tokushige
- Abstract
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
- Subjects
HEMAPHERESIS; GRANULOCYTE antigens; COVID-19 pandemic
- Publication
Intestinal Research, 2022, Vol 20, Issue 1, p150
- ISSN
1598-9100
- Publication type
Article
- DOI
10.5217/ir.2020.00148